FuRui Medical Technology expands its business in Asia and opens a new regional office in Tianjin, China

FuRui Medical Technology (English “Sisram Medical”, stock code: 1696.HK), a medical technology operating platform focusing on the medical and aesthetic health industry$SISRAM MED (01696.HK)$Today, it was announced that it will expand its business in China and the Asia-Pacific region.

The newly established FuRui Medical Technology China Office will carry out a series of business activities to continuously explore potential cooperation opportunities with Fosun Pharmaceuticals (stock code: 600196.SH/02196.HK) and build a collaborative ecosystem. Preliminary plans include: cosmetic dentistry, NMPA registration and sale of facial injection fillers, and construction of regional service centers and regional warehouses.

The Regional Office of FuRui Medical Technology is located in the Tianjin Pilot Free Trade Zone. Mr. Liu Yi, President of Fosun Pharmaceutical's Medical Devices Division and Chairman of FuRui Medical Technology, is the head. The appointment reflects Fosun Pharma's confidence and long-term plans for FuRui Medical Technology's business development in China and the Asia-Pacific region.

Through a joint venture with Fosun Pharmaceuticals, the China Office of FuRui Medical Technology Co., Ltd. (hereinafter referred to as “Tianjin Xingmei”), established a new drug fund, officially put into operation. Tianjin Xingmei recently announced that it has signed a license agreement with Israel's Raziel Therapeutics (RT) Ltd. (hereinafter referred to as “Raziel”) to obtain the exclusive right to clinically develop and commercialize its injectable product RZL012 in mainland China, Hong Kong, Macao and Taiwan. RZL-012 is the first long-acting single-treatment injection product used in beauty and treatment.

Mr. Liu Yi, Chairman of FuRui Medical Technology, said, “The new regional office will continue to implement FuRui Medical Technology's business philosophy. We will use the synergy of regional business to provide a complete set of solutions for the medical and aesthetic health market.”

Lior Dayan, CEO of FuRui Medical Technology, said, “China is the focus of our global strategy. The establishment of the Tianjin office shows our ambitions and plans for development in China and the Asia-Pacific region. Over the next few years, we will focus on expanding new business in China and with multinational and local companies from around the world.”

About FuRei Medical Technology

FuRui Medical Technology (stock code: 1696.HK) is one of the top five global leaders in the energy source medical beauty industry, and is a holding subsidiary of Fosun Pharmaceutical, a leading healthcare industry group in China. FuRui Medical Technology was listed in Hong Kong on September 19, 2017. It is the first Israeli company to be listed on the main board of the Hong Kong Stock Exchange. Its core subsidiary, Alma Lasers, is a leading global provider of energy source surgical and medical aesthetic equipment, operating in more than 90 countries and regions around the world. The company's flagship products include: (i) the [Soprano] series, which is mainly used for laser hair removal; (ii) the [Harmony] series, a multi-functional multi-application platform that can be used for more than 65 FDA approved indications; (iii) the [Accent] series, which is mainly used for body shaping and skin tightening, all of which belong to the medical aesthetic product line; (iv) [FemiLift], a minimally invasive medical aesthetic device for various female problems; and (v) [BeautiFill] by LipoFlow platform, the first FDA-approved platform It is also currently the only energy source device used for autologous fat transplantation. In addition, the company has also entered the injectable market and has sales in Israel and Hong Kong, China.

FuRui Medical Technology Improves Quality of Life

http://www.sisram-medical.com

Media contacts

China:

Edmond Lococo Managing Director

ICR Asia

+ 86 (10) 6583-7510

Edmond.lococo@icrinc.com

Sisram Medical Clinician its APAC Operation, Opening a New Regional Office in Tianjin, China

Sisram Medical Ltd (“Sisram” or “the Company”) (Hong Kong: 1696), an operational holding company designed in medical aesthetics technology for wellness, today introduced the expansion of its business with a new office to serve China and the greater Asia Pacific region.

Sisram Medical's newly founded office in China will handle various business activities involving the beneficial ecosystem and potential synergies between Sisram and its majority Shareholder, Fosun Pharma (Fosun Pharma, stock code: 600196.SH, 02196.HK). Combining the first activities the new office will oversee are: aesthetic dentistry, registration of dermal facial fillers with China's National Medical Products Administration (NMPA), and the Combinations of a regional service center and regional warehouse.

Sisram Medical's new regional office is located in China's Tianjin Pilot Free Trade Zone and will be headed by Mr. Liu Yi, the Officers of Sisram Medical, and President of the Medical Devices Division of Fosun Pharma. The Appointment of Mr. Liu Yi is a testament to Fosun Pharma's trust and the promise of its future plans for Sisram Medical's business operation in China and the greater APAC region.

The Tianjin Office was funded with a first investment in a start-up company that was incubated by Fosun Pharma's venture capital fund. The startup company, named Tianjin JuveStar Biotech Co., Ltd., (JuveStar), recently signed the signing of a license agreement with Raziel Therapeutics.

The agreement provides JuveStar with exclusive rights to develop and commercialize Raziel's Injectable RZL-012, an Exciting Injectable Product for Aesthetic Injectable and Additional Therapeutic fields, in mainland China, Hong Kong, Macau and Taiwan. RZL-012 is the first, most effective single treatment injectable product for aesthetic and therapeutic applications.

“The New Regional Office Echoes Sisram's Philosophy by Combining an Umbrella of Solutions for the Wellness Market, Leveraging Our Synergistic Affiliation and Local Business Affiliations” said Mr. Liu

Lior Dayan, CEO of Sisram Medical said, “China is a global strategic priority for us. The opening of our local office in Tianjin is a clear statement of the company's planned growth plans for the country in specific, and the region in general. We are committed to develop new and additional business with international and Chinese companies in China in the coming years.”

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is one of the top 5 global leaders in the energy-based medical aesthetics industry. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board. Sisram Medical's core medicine, Alma, is a global leading provider of energy-based surgical and medical aesthetics solutions and is active across 90 countries and conditions worldwide. Flagship Systems of Sisram Medical include (i) the “Soprano” family, specially used for laser hair removal; (ii) the “Harmony” family, a versatile multi-application platform that can be used TO TREAT MORE THAN 65 DIFFERENT FDA-LENGTH; (iii) THE “ACCENT” FAMILY, USED FOR BODY CONTOURING AND SKIN TIGHTENING; (iv) “FEMILift”, a minimally effective treatment system for various regulatory conditions; and (v) “Beautifill” by LipoFlow platform, the first and only energy-based device prepared by the FDA for autologous fat grafting. In addition, Sisram Medical also contains the injectables market, with products available in Israel and Hong Kong.

Sisram Medical — Intact Quality of Life.

http://www.sisram-medical.com

For media suggestions, please contact:

ICR Inc.

Edmond Lococo

Tel: + 86 (10) 6583-7510

E-mail: Edmond.lococo@icrinc.com

69K Views